Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05196828 · ClinicalTrials.gov registry record · NA
Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS
A NA study, sponsored by Noctrix Health.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT05196828 is a NA study that has completed, run by Noctrix Health. The registered enrollment target is 103 participants.
The verdict
NCT05196828, a NA study, has completed, sponsored by Noctrix Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
Multi-center, prospective open-label extension study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate- severe primary RLS
Interventions
- DEVICE NTX100 Neuromodulation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2022-11-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05196828
The ClinicalTrials.gov registry entry for NCT05196828 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noctrix Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NTX100 Neuromodulation System is the first listed.
NCT05196828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05196828 about?
NCT05196828 is a clinical study titled "Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS". Multi-center, prospective open-label extension study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate- severe primary RLS
What is the current status of trial NCT05196828?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2021-12-20. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT05196828?
The interventions under investigation include: NTX100 Neuromodulation System (DEVICE).
Who is sponsoring clinical trial NCT05196828?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.